CJC-1295 vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 100 mcg
- 10 mg per day
- Frequency
- Once daily, before bed
- Daily for 10–30 days
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —